Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 12/20 | 0.46 |
| ▸ | HTR2A | P28223 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 4/20 | 0.43 |
| ▸ | CCND1 | P24385 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377396 | 0.81 | HTR1A (0.51) | HTR2CHTR2AKDM4EMEN1TP53 | |
| SCHEMBL11881460 | 0.67 | HTR2C (0.61) | HTR2CHTR2AKDM4EMEN1TP53 | |
| Hydrochloric Acid SCHEMBL7001168 | 0.66 | HTR2C (0.52) | HTR2CHTR2AKDM4EMEN1TP53 | |
| SCHEMBL1752535 | 0.65 | HTR1A (0.71) | HTR1ADRD2 | |
| SCHEMBL5141708 | 0.65 | HTR1A (0.71) | HTR1ADRD2 | |
| SCHEMBL29462303 | 0.63 | HTR2C (1.00) | HTR2CHTR2AKDM4EMEN1TP53 | |
| SCHEMBL4352456 | 0.63 | HTR2C (1.00) | HTR2CHTR2AKDM4EMEN1TP53 | |
| SCHEMBL7669760 | 0.63 | HTR2C (1.00) | HTR2CHTR2AKDM4EMEN1TP53 | |
| SCHEMBL29407494 | 0.62 | PARP1 (0.50) | HTR2CHTR2AKDM4EMEN1TP53 | |
| SCHEMBL19305557 | 0.62 | PARP1 (0.50) | HTR2CHTR2AKDM4EMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082685-A1 | METHODS FOR ATTENUATING VIRAL INFECTION AND FOR TREATING LUNG INJURY | Spiritus Therapeutics, Inc. (US) | 2025-03-13 | — | — | US | claimed |
| CN-118485358-B | Optimization configuration method for distributed blockchain production logistics resources based on improved teaching and learning algorithm | 暨南大学 | 2025-02-07 | — | — | CN | claimed |
| CN-118485358-A | Optimization configuration method for distributed blockchain production logistics resources based on improved teaching and learning algorithm | 暨南大学 | 2024-08-13 | — | — | CN | claimed |
| WO-2023081299-A9 | A PURIFIED ENRICHED POPULATION EXOSOMES DERIVED FROM INDIVIDUALS WITH A CHRONIC PROGRESSIVE LUNG DISEASE FOR NONINVASIVE DETECTION, STAGING, AND MEDICAL MONITORING OF DISEASE PROGRESSION | Spiritus Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | claimed |
| EP-4267958-A2 | METHOD FOR SMALL-RNA BIOMARKER IDENTIFICATION AND FUNCTIONAL EVALUATION OF CIRCULATING EXTRACELLULAR VESICLES COMPRISING EXOSOMES | Hackensack Meridian Health Center for Discovery and Innovation (US) | 2023-11-01 | — | — | EP | claimed |
| WO-2023178169-A2 | COMPOSITIONS AND METHODS FOR TREATING THE PATHOPHYSIOLOGY OF SEVERE VIRAL INFECTION | ANEMOI BIOTECH HOLDINGS, INC. (US) | 2023-09-21 | — | — | WO | claimed |
| WO-2023081299-A1 | A PURIFIED ENRICHED POPULATION EXOSOMES DERIVED FROM INDIVIDUALS WITH A CHRONIC PROGRESSIVE LUNG DISEASE FOR NONINVASIVE DETECTION, STAGING, AND MEDICAL MONITORING OF DISEASE PROGRESSION | Spiritus Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | claimed |
| US-20230147720-A1 | Purified Enriched Population Exosomes Derived From Individuals With A Chronic Progressive Lung Disease For Noninvasive Detection, Staging, And Medical Monitoring Of Disease Progression | Spiritus Therapeutics, Inc. (US) | 2023-05-11 | — | — | US | claimed |
| US-20220401477-A1 | METHOD FOR CONTROLLING VIRAL INFECTIONS THROUGH ADOPTIVE TRANSFER OF A CELL PRODUCT COMPRISING AN EXPANDED AND ENRICHED POPULATION OF SUPERACTIVATED CYTOKINE KILLER CELLS | VERDURE BIOTECH, INC. (US) | 2022-12-22 | — | — | US | claimed |
| WO-2022245813-A2 | A METHOD FOR CONTROLLING VIRAL INFECTIONS THROUGH ADOPTIVE TRANSFER OF A CELL PRODUCT COMPRISING AN EXPANDED AND ENRICHED POPULATION OF SUPERCTIVATED CYTOKINE KILLER CELLS | VERDURE BIOTECH, INC. (US) | 2022-11-24 | — | — | WO | claimed |
| WO-2022140662-A2 | METHOD FOR SMALL-RNA BIOMARKER IDENTIFICATION AND FUNCTIONAL EVALUATION OF CIRCULATING EXTRACELLULAR VESICLES COMPRISING EXOSOMES | Hackensack Meridian Health Center For Discovery and Innovation (US) | 2022-06-30 | — | — | WO | claimed |
| EP-2308885-B1 | Novel compounds and methods for therapy | GILEAD SCIENCES INC (US) | 2014-11-19 | — | — | EP | claimed |
| EP-2245037-B1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | GILEAD SCIENCES INC (US) | 2014-06-18 | — | — | EP | claimed |
| EP-2308885-A2 | Novel compounds and methods for therapy | Gilead Sciences, Inc. (US) | 2011-04-13 | — | — | EP | claimed |
| US-20090317418-A1 | VACCINES AND METHODS FOR PREVENTION AND TREATMENT OF DRUG-RESISTANT HIV-1 AND HEPATITIS B VIRUS | THE GOV'T OF USOA as represented by the SECRETARY OF THE DEPT OF HHS (US) | 2009-12-24 | — | — | US | claimed |
| US-20090232768-A1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | GILEAD SCIENCES, INC. (US) | 2009-09-17 | — | — | US | claimed |
| WO-2008134578-A2 | SYNTHESIS OF OPTICALLY ACTIVE RADIO-LABELED REVERSE TRANSCRIPTASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF (US) | 2008-11-06 | — | — | WO | claimed |
| US-12607589-B2 | Methods, assays and systems for detection of a target analyte | SORRENTO THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| WO-1993006106-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE IMIDAZO[4,5,1-jk][1,4]-BENZODIAZEPIN-2(1H^_)-THIONES | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-04-01 | — | — | WO | disclosed |
| EP-0454427-A1 | Antiretroviral bases | Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic (CZ) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401477-A1 | METHOD FOR CONTROLLING VIRAL INFECTIONS THROUGH ADOPTIVE TRANSFER OF A CELL PRODUCT COMPRISING AN EXPANDED AND ENRICHED POPULATION OF SUPERACTIVATED CYTOKINE KILLER CELLS | IFNG, PBK, IL4 | HTR2C 3989/4885HTR2A 4388/4885KDM4E 3355/4885 |
| US-12607589-B2 | Methods, assays and systems for detection of a target analyte | PRSS3, PRSS2, ZP1 | HTR2C 3465/4885HTR2A 3764/4885KDM4E 4126/4885 |
| US-20090232768-A1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | TP53, ZC3HAV1, ZFX | HTR2C 4054/4885HTR2A 4056/4885KDM4E 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.